Impact of Product Patent Regime on Pharmaceutical Companies in India

Khan, Shazli Ahmed; Nasim, Saboohi

doi:10.1007/978-81-322-2834-9_18

Cited by 3 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Novartis’ Gleevec has not been patented in India, but Novartis still said it respects the Indian court's decision. In recent years, India has also used the provisions of the Doha Declaration to grant compulsory production licenses to some drugs in accordance with the law, which is not a blind compulsory license that violates international law (Khan and Nasim, 2016).…”

Section: Global Competitiveness Of Indian Pharmaceuticalsmentioning

confidence: 99%

China–India pharmaceutical industry cooperation in the context of “One Belt, One Road”: Opportunities, challenges, and the way forward

Farooq

Feroze

Iftikhar³

et al. 2022

Asian Journal of Comparative Politics

View full text Add to dashboard Cite

To promote the “Belt and Road Initiative” (BRI) in India, it is necessary to highlight the economic attributes, highlight the role of the market, cultivate new growth points of cooperation, and consolidate the foundation of common interests. Industrial cooperation is an important part not only of the “Belt and Road” construction, but also of economic cooperation between the countries. The pharmaceutical product industry is India's most advantageous industry, and it is also an industry with which India hopes to strengthen cooperation with China. In the context of “One Belt, One Road,” China–India pharmaceutical industry cooperation faces both rare opportunities and some challenges, but from the perspective of development trends, obstacles are gradually reducing. Promoting Sino–Indian pharmaceutical industry cooperation requires the joint efforts of government departments, industry chambers of commerce, and pharmaceutical companies. The key is to choose the right cooperation field and path. Strengthening China–India pharmaceutical industry cooperation is conducive to fostering new growth points for China–India economic cooperation, reducing India's concerns about the BRI, and promoting the BRI in India and the entire South Asian region.

show abstract

Section: Global Competitiveness Of Indian Pharmaceuticalsmentioning

confidence: 99%

China–India pharmaceutical industry cooperation in the context of “One Belt, One Road”: Opportunities, challenges, and the way forward

Farooq

Feroze

Iftikhar³

et al. 2022

Asian Journal of Comparative Politics

View full text Add to dashboard Cite

show abstract

“…In the absence of equity-based relationships, knowledge acquisition is most likely to occur through internal mechanisms, such as R&D, or externally through royalties and licenses. The TRIPS regime gave greater protection to inventors, leading to a two-pronged reaction by Indian firms: (1) augmenting their own research capabilities in order to transition from core process research to new drug development, and (2) sourcing external knowledge by forging commercial alliances with global companies (Khan & Nasim, 2016).…”

Section: Knowledge Sourcing and International Business Activitymentioning

confidence: 99%

“…With the TRIPS agreement changing the nature of the IP regime, Indian pharmaceutical firms began to forge commercial alliances with foreign inventors, aimed at sourcing knowledge (Khan & Nasim, 2016). India's emerging-market status and the technological nature of the industry made external knowledge sourcing particularly important for international competitiveness for several reasons.…”

Section: Knowledge Sourcing and International Business Activitymentioning

confidence: 99%

Knowledge Sources and International Business Activity in a Changing Innovation Ecosystem: A Study of the Indian Pharmaceutical Industry

2019

View full text Add to dashboard Cite

The Indian pharmaceutical industry has experienced rapid growth, becoming the world's largest provider of generic drugs, based on product and process innovation. The industry has undergone dynamic changes in recent decades, operating in a rapidly evolving environment affected by domestic and global policies; a key example of the latter is the TRIPS agreement. Taking an intellectual property perspective, we describe how changes in the innovation ecosystem have affected companies’ strategies related to international activity and accessing knowledge from both internal and external knowledge sources, during the transitional- and post-TRIPS periods (1995–2004 and 2005–2014, respectively). Combining intellectual property arguments with contextual aspects of the innovation ecosystem, we conjecture that, in the post-TRIPS period, externally-sourced knowledge will be more important than internally-sourced knowledge, for Indian pharmaceutical firms’ international business activity.

show abstract

Pharmaceutical growth versus health equity in India: when markets fail

Mukhopadhyay

Paul

2018

J Public Health (Berl.)

View full text Add to dashboard Cite

Impact of Product Patent Regime on Pharmaceutical Companies in India

Cited by 3 publications

References 2 publications

China–India pharmaceutical industry cooperation in the context of “One Belt, One Road”: Opportunities, challenges, and the way forward

China–India pharmaceutical industry cooperation in the context of “One Belt, One Road”: Opportunities, challenges, and the way forward

Knowledge Sources and International Business Activity in a Changing Innovation Ecosystem: A Study of the Indian Pharmaceutical Industry

Pharmaceutical growth versus health equity in India: when markets fail

Contact Info

Product

Resources

About